Nouscom Names Loredana Siani Chief Technology Officer
The promotion comes as the Basel-based gene therapy developer advances its NOUS-209 program following a €120 million Series D financing.
Updated on Nov. 2, 2026 in Biotech
Nouscom has promoted Loredana Siani, Ph.D., to Chief Technology Officer, effective immediately. The company also closed a €120 million ($135 million) Series D financing to advance its NOUS-209 program.
Why it matters
The promotion comes as Nouscom enters a pivotal stage of clinical development, with NOUS-209 set to advance into a registration-enabling trial in Lynch Syndrome carriers. Siani's elevation signals a focus on technical and manufacturing readiness for commercial-scale production.
Nouscom's proprietary viral vectors are manufactured as both off-the-shelf and individualized products using a small-scale, fully automated closed system developed by Siani's team. The company has secured regulatory clearance for its clinical trial material and manufacturing and release processes.
The players
Nouscom
A Basel, Switzerland-based biotechnology company developing viral vector-based therapies, including its NOUS-209 program for Lynch Syndrome.
Loredana Siani, Ph.D.
Nouscom's newly appointed Chief Technology Officer, who holds a Ph.D. in Industrial Biotechnology Science from the University Federico II in Naples and an Executive MBA from Luiss Business School in Rome.
Concetta Baldo
Nouscom's newly promoted Head of Clinical Operations, who holds an M.Sc. in Chemistry and Pharmaceutical Technology.
The details
Siani, who joined Nouscom in 2020, most recently served as Senior Vice President, Technical CMC, and will continue to lead the technical organization with responsibility for CMC, commercial-scale manufacturing, and technical operations. Concetta Baldo has also been promoted to Head of Clinical Operations, bringing more than 15 years of clinical research experience.
Timeline
2020: Loredana Siani joins Nouscom.
November 2, 2026: Nouscom announces Siani's promotion to Chief Technology Officer.
The Tech Race
Nouscom's proprietary viral vector platform, which has supplied multiple clinical studies across North America and Europe, is now being scaled toward commercial-scale manufacturing. The leadership change positions the company's technical organization to carry that platform from clinical supply into registration-enabling work for NOUS-209.
For patients and clinicians tracking gene therapy pipelines, the advancement of NOUS-209 into a registration-enabling trial could eventually expand treatment options for Lynch Syndrome carriers. The timeline for that trial and any resulting access remains unannounced.
The takeaway
Leadership changes at biotech companies often signal a shift from development into manufacturing and clinical execution. Nouscom's elevation of its technical leader suggests the company is preparing its platform for the next phase of scale.
Further reading
Explore more biotech developments shaping gene therapy and clinical manufacturing.
